Susceptibility may be the key, says ViroLogic:
This article was originally published in Clinica
After years spent studying HIV drug resistance, ViroLogic now believes that the opposite phenomenon, viral hypersusceptibility, may offer a way to improve treatment for HIV-infected patients. In a retrospective study of 30 treatment-experienced patients published in AIDS (June 15th), ViroLogic researchers found that the reduction in viral load following treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs) was 20 times higher in patients with virus that was hypersusceptible to NNRTIs, and no resistance-related mutations, than in those with virus showing normal sensitivity to the drugs. Viral sensitivity was determined using the South San Francisco, California company's PhenoSense HIV drug resistance assay.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.